Icomas (Methane, Acetylene, Carbon Monoxide)

The gases in Icomas modify the composition of inhaled air, affecting alveolar partial pressures. Methane and acetylene are largely inert, serving as carrier gases, while low‑level carbon monoxide can bind to hemoglobin and influence cellular signaling pathways, together allowing clinicians and researchers to adjust respiratory physiology in a controlled manner.

The dose of Icomas is determined by the prescribing clinician based on the specific therapeutic or research protocol, the desired gas concentration, and patient characteristics. Administration is typically measured in volume percent of the gas mixture delivered through calibrated delivery systems, and exact dosing instructions are provided in the relevant clinical guideline or study protocol.

Safety data for Icomas in pregnant or lactating individuals are limited. Because carbon monoxide can cross the placenta and be excreted in breast milk, caution is advised, and the product should only be used during pregnancy or breastfeeding when the potential benefits outweigh the known risks and under strict medical supervision.

To order Icomas, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and assistance with import documentation.

Compared with standard oxygen therapy or nitrous oxide, Icomas offers a unique combination of inert carrier gases (methane, acetylene) and a low concentration of carbon monoxide, enabling specific modulation of vascular tone and cellular signaling not achievable with oxygen alone. However, its use requires specialized equipment and monitoring, whereas conventional gases are more widely available and have well‑established safety profiles.

Icomas cylinders should be stored at ambient temperature, in a well‑ventilated, temperature‑controlled area away from direct sunlight, heat sources, and ignition points. Cylinders must be secured upright, protected from corrosion, and handled only by trained personnel using appropriate gas‑handling equipment and personal protective gear.

Icomas is administered by inhalation using calibrated gas delivery systems such as ventilators, gas mixers, or specialized inhalation chambers. The gas is blended to the prescribed concentration and delivered to the patient’s airway, with continuous monitoring of respiratory parameters, oxygen saturation, and hemodynamic status to ensure safety and therapeutic efficacy.

The most serious risks include carbon monoxide poisoning, which can lead to hypoxic injury, myocardial ischemia, loss of consciousness, and in severe cases, death. Additionally, the flammable nature of methane and acetylene poses fire and explosion hazards if proper safety protocols are not followed during storage and administration.

Icomas should be avoided in patients with known hypersensitivity to carbon monoxide, severe chronic obstructive pulmonary disease, uncontrolled asthma, or any condition where exposure to flammable gases could pose a safety risk. It is also contraindicated in settings lacking appropriate gas monitoring, ventilation, and emergency response capabilities.